Iqvia (NYSE:IQV) Price Target Raised to $195.00 at Citigroup

Iqvia (NYSE:IQV) had its price target raised by Citigroup from $185.00 to $195.00 in a research note released on Thursday morning, The Fly reports. They currently have a buy rating on the medical research company’s stock.

IQV has been the topic of several other research reports. Zacks Investment Research upgraded Iqvia from a sell rating to a hold rating and set a $170.00 target price on the stock in a report on Tuesday, February 4th. Stifel Nicolaus boosted their price target on Iqvia from to and gave the stock a buy rating in a research report on Wednesday. Wells Fargo & Co initiated coverage on Iqvia in a research report on Tuesday, January 7th. They set an overweight rating and a $180.00 price target on the stock. Cfra raised Iqvia from a hold rating to a buy rating and boosted their price target for the stock from $148.00 to $185.00 in a research report on Wednesday. Finally, ValuEngine downgraded Iqvia from a hold rating to a sell rating in a research report on Tuesday, February 4th. One research analyst has rated the stock with a sell rating, two have given a hold rating and seventeen have given a buy rating to the company. The stock presently has an average rating of Buy and a consensus target price of $174.30.

Shares of Iqvia stock traded down $1.47 during trading on Thursday, reaching $164.32. The stock had a trading volume of 2,962,308 shares, compared to its average volume of 1,312,776. The company has a market capitalization of $31.03 billion, a price-to-earnings ratio of 134.69, a P/E/G ratio of 1.70 and a beta of 0.91. The stock has a fifty day moving average price of $158.20 and a two-hundred day moving average price of $151.72. Iqvia has a 52 week low of $130.77 and a 52 week high of $169.14. The company has a current ratio of 1.12, a quick ratio of 1.12 and a debt-to-equity ratio of 1.85.

Iqvia (NYSE:IQV) last released its earnings results on Wednesday, February 12th. The medical research company reported $1.74 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.72 by $0.02. Iqvia had a return on equity of 16.95% and a net margin of 2.24%. The business had revenue of $2.90 billion for the quarter, compared to analyst estimates of $2.85 billion. During the same quarter in the prior year, the company posted $1.50 earnings per share. Iqvia’s revenue was up 7.7% on a year-over-year basis. On average, equities analysts forecast that Iqvia will post 5.9 EPS for the current fiscal year.

In other news, CFO Michael R. Mcdonnell sold 12,000 shares of the stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $155.07, for a total value of $1,860,840.00. Following the completion of the transaction, the chief financial officer now directly owns 14,366 shares in the company, valued at approximately $2,227,735.62. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Michael J. Evanisko sold 6,250 shares of the stock in a transaction on Friday, January 31st. The shares were sold at an average price of $155.19, for a total value of $969,937.50. The disclosure for this sale can be found here. Insiders have sold 37,000 shares of company stock valued at $5,830,215 over the last 90 days. Corporate insiders own 6.00% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the company. Montag & Caldwell LLC increased its holdings in Iqvia by 3.3% in the third quarter. Montag & Caldwell LLC now owns 2,840 shares of the medical research company’s stock valued at $424,000 after purchasing an additional 90 shares during the period. D.A. Davidson & CO. increased its holdings in Iqvia by 10.0% in the third quarter. D.A. Davidson & CO. now owns 12,102 shares of the medical research company’s stock valued at $1,808,000 after purchasing an additional 1,102 shares during the period. Carroll Financial Associates Inc. increased its holdings in Iqvia by 186.8% in the fourth quarter. Carroll Financial Associates Inc. now owns 370 shares of the medical research company’s stock valued at $57,000 after purchasing an additional 241 shares during the period. Worldquant Millennium Advisors LLC acquired a new stake in Iqvia in the third quarter valued at $3,982,000. Finally, Third Point LLC increased its holdings in Iqvia by 25.0% in the third quarter. Third Point LLC now owns 2,000,000 shares of the medical research company’s stock valued at $298,760,000 after purchasing an additional 400,000 shares during the period. Institutional investors own 89.93% of the company’s stock.

Iqvia Company Profile

IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Recommended Story: How is the discount rate different from the Federal Funds rate?

The Fly

Analyst Recommendations for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.